Status:
COMPLETED
Combination of Recombinant Human IL-21 (rIL-21) and Sunitinib in Stage IV Renal Cell Carcinoma Patients
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Cancer
Renal Cell Carcinoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This phase 1/2a trial is conducted in Europe. The first part of the trial is a dose escalation safety trial determining the maximum tolerated dose of rIL-21 when administered in combination with sunit...
Eligibility Criteria
Inclusion
- Histologically verified and surgically incurable stage IV Renal Cell Carcinoma
- ECOG performance status of 0 or 1 (i.e. good performance status)
- Life expectancy of at least 3 months
Exclusion
- Prior systemic therapy for metastatic disease
- Radiotherapy within the last 4 weeks prior to start of treatment
- Receipt of any investigational drug within 3 months of starting treatment
- History of any other active malignancy within five years prior to enrolment
Key Trial Info
Start Date :
July 12 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 30 2008
Estimated Enrollment :
9 Patients enrolled
Trial Details
Trial ID
NCT00617253
Start Date
July 12 2007
End Date
June 30 2008
Last Update
March 1 2017
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Frankfurt, Germany, 60488
2
Novo Nordisk Investigational Site
Hamburg, Germany, 20246
3
Novo Nordisk Investigational Site
Hanover, Germany, 30625
4
Novo Nordisk Investigational Site
Amsterdam, Netherlands, 1066 CX